Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. More Details
+ 1 more risk
Excellent balance sheet with limited growth.
Share Price & News
How has Cann Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CAN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CAN underperformed the Australian Pharmaceuticals industry which returned -32.4% over the past year.
Return vs Market: CAN underperformed the Australian Market which returned -9.6% over the past year.
Price Volatility Vs. Market
How volatile is Cann Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StHere's Why Cann Group (ASX:CAN) Can Afford Some Debt
4 months ago | Simply Wall StCann Group Limited (ASX:CAN) Is Expected To Breakeven
6 months ago | Simply Wall StWhat Kind Of Investor Owns Most Of Cann Group Limited (ASX:CAN)?
Is Cann Group undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CAN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CAN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CAN is unprofitable, so we can't compare its PE Ratio to the XO Pharmaceuticals industry average.
PE vs Market: CAN is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CAN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CAN is good value based on its PB Ratio (0.7x) compared to the AU Pharmaceuticals industry average (3.4x).
How is Cann Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CAN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CAN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CAN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CAN's revenue (59.9% per year) is forecast to grow faster than the Australian market (4.8% per year).
High Growth Revenue: CAN's revenue (59.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CAN is forecast to be unprofitable in 3 years.
How has Cann Group performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CAN is currently unprofitable.
Growing Profit Margin: CAN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CAN is unprofitable, and losses have increased over the past 5 years at a rate of 40.8% per year.
Accelerating Growth: Unable to compare CAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (117.8%).
Return on Equity
High ROE: CAN has a negative Return on Equity (-27.73%), as it is currently unprofitable.
How is Cann Group's financial position?
Financial Position Analysis
Short Term Liabilities: CAN's short term assets (A$12.5M) exceed its short term liabilities (A$6.5M).
Long Term Liabilities: CAN's short term assets (A$12.5M) exceed its long term liabilities (A$8.8M).
Debt to Equity History and Analysis
Debt Level: CAN's debt to equity ratio (13.4%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if CAN's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CAN has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CAN is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.
What is Cann Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CAN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CAN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CAN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CAN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Peter Crock, B.Ag.Sci (Hons), MBA has been Chief Executive Officer at Cann Group Limited since May 23, 2016. Mr. Crock is an experienced public company senior manager with strong skills in marketing an ...
CEO Compensation Analysis
Compensation vs Market: Peter's total compensation ($USD346.31K) is about average for companies of similar size in the Australian market ($USD274.23K).
Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.
|Chief Executive Officer||4.42yrs||AU$492.07k||0.13% |
|Chief Financial Officer||0.42yr||AU$444.63k||no data|
|Chief Operating Officer||0.25yr||AU$298.44k||no data|
|Chief Projects & Information Officer||0.25yr||AU$3.76m||no data|
|Chief Compliance Officer & Company Secretary||0.83yr||AU$275.66k||no data|
|Head of Investor Relations||no data||no data||no data|
|Head of Legal||no data||AU$204.01k||0% |
Experienced Management: CAN's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CAN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 90.3%.
Cann Group Limited's company bio, employee growth, exchange listings and data sources
- Name: Cann Group Limited
- Ticker: CAN
- Exchange: ASX
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$80.973m
- Shares outstanding: 269.91m
- Website: https://www.canngrouplimited.com
- Cann Group Limited
- Walter & Eliza Hall Inst. of Medical Res
- 4 Research Avenue
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CAN||ASX (Australian Securities Exchange)||Yes||Ordinary Shares||AU||AUD||May 2017|
|CAN||CHIA (Chi-X Australia)||Yes||Ordinary Shares||AU||AUD||May 2017|
|CVJ||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||May 2017|
|CNGG.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||May 2017|
Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/31 10:44|
|End of Day Share Price||2020/10/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.